The protective Ag of Shigella, the Gram-negative enteroinvasive bacterium causing bacillary dysentery, or shigellosis, is its O-specific polysaccharide (O-SP) domain of the LPS, the major bacterial surface component. As an alternative to the development of detoxified LPS-based conjugate vaccines, recent effort was put into the investigation of neoglycoproteins encompassing synthetic oligosaccharides mimicking the protective Ags of the O-SP. We previously reported that when coupled to tetanus toxoid via single point attachment, a synthetic pentadecasaccharide representing three biological repeating units of the O-SP of Shigella flexneri 2a (SF2a), one of the most common Shigella serotypes, elicits a better serum anti-LPS 2a Ab response in mice than shorter synthetic O-SP sequences. In this study, we show that the pentadecasaccharide-induced anti-LPS 2a Abs protect passively administered naive mice from Shigella infection. Therefore, this three repeating units sequence, which is recognized by anti-SF2a sera from infected patients, acts as a functional mimic of the native polysaccharide Ag. Analyses of parameters influencing immunogenicity revealed that an investigational SF2a vaccine displaying a pentadecasaccharide:tetanus toxoid molar loading of 14:1 triggers a high and sustained anti-LPS Ab response, without inducing anti-linker Ab, when administered four times at a dose corresponding to 1 g of carbohydrate. In addition, the profile of the anti-LPS Ab response, dominated by IgG1 production (Th2-type response), mimics that observed in human upon natural SF2a infection. This synthetic carbohydrate-based conjugate may be a candidate for a SF2a vaccine.
P
arenterally administered polysaccharide-protein conjugate vaccines have been shown to be more effective than the first generation of polysaccharide vaccines made of purified polysaccharide Ags. Interestingly, all licensed second generation polysaccharide vaccines target capsulated bacteria (1) , and there is no commercialized LPS-based conjugate vaccine. The toxicity of lipid A (i.e., endotoxin), a major component of LPS, which precludes its use in conjugate vaccines, largely accounts for the current situation. LPS-detoxification is a prerequirement to the development of LPS-based conjugate vaccines. Despite this difficulty, vaccine candidates derived from LPS lacking full-length lipid A-chains are under investigation (2) (3) (4) (5) (6) . Alternatively, progress in glycochemistry has opened the way to third generation polysaccharide vaccines, namely, synthetic carbohydrate-protein conjugate vaccines (7) (8) (9) (10) .
Shigella, a Gram-negative enteroinvasive bacterium causing shigellosis, is a major public-health concern worldwide (11) (12) (13) .
Shigellosis is endemic in areas with a low level of hygiene, mainly targeting children under 5 years of age. There is as of yet no broadly licensed vaccine for this common serious disease (14) . S. flexneri 2a (SF2a), 4 a member of Shigella Group B, remains the most common Shigella worldwide (12) . In addition, in countries where the disease is endemic, several S. flexneri serotypes are isolated. However, their distribution varies based on geographical areas (12) . Serological classification is based on the nature of the repeating unit (RU) (15, 16) of the O-specific polysaccharide (O-SP) moiety of LPS, which acts as a major virulence factor for Shigella, providing the bacterium with resistance to host defense mechanisms (15) . Protection induced by natural infection is considered serotype-specific, pointing to the O-SP as the major target of protection. Early on, the protective role of anti-O-SP serum IgGs, through killing of Shigella inoculum on the epithelium surface of small intestine, was hypothesized (2, 17) . It was subsequently supported by clinical data (18) and reports on the immunogenicity of Shigella detoxified LPS-protein conjugates in adults (19) and in young children (20) . In addition, it was recently suggested that such Abs might be curative (4) .
We initiated a program aimed at developing a third generation carbohydrate-based vaccine against SF2a infection. The strategy is based on the use of synthetic oligosaccharides (OSs), acting as efficient functional SF2a O-SP mimics, as the haptens for a conjugate vaccine. Therefore, the crucial LPS detoxification step is avoided. Following the synthesis of a large panel of SF2a O-SP fragments (21) (22) (23) (24) (25) (26) and extensive investigation of their recognition by protective murine monoclonal IgG (mIgG) Abs, we showed that selected synthetic OSs induced an anti-O-SP Ab response in mice, when administered as tetanus toxoid (TT) conjugates. Increasing the length of the carbohydrate hapten from a penta-to a deca-and pentadecasaccharide representing one, two, and three biological RUs of SF2a O-SP (Fig. 1) , respectively, improves the anti-LPS 2a IgG response (27) . Here, we report on the protective capacity of those glycoconjugate-induced anti-LPS Abs against SF2a infection in mice, and show that the pentadecasaccharide [AB(E)CD] 3 is a functional mimic of the natural polysaccharide Ag. We also assess the different parameters influencing immunogenicity in mice. Finally, we present preclinical data demonstrating that [AB(E)CD] 3 -TT is a candidate for a synthetic carbohydrate-protein conjugate vaccine against SF2a infection.
Materials and Methods

Bacterial strains
S. flexneri 454, an invasive isolate of SF2a was the virulent strain of reference. For intranasal (i.n.) infection, bacteria were routinely grown on Luria-Bertani agar plates at 37°C, recovered from the plates, and diluted with 0.9% NaCl to an OD of 1 at 600 nm (5 ϫ 10 8 CFU/ml). For counting of bacteria upon i.n. infection, lungs were recovered en bloc after cervical dislocation of mice and ground in 10 ml of sterile PBS (Ultra turrax T25 apparatus, IKA-Werke). Dilutions were then plated on trypticase soy broth plates for enumeration.
Semi-synthetic glycoconjugates
The general synthetic and analytical protocols used to obtain the TTconjugates have been previously described (27) . Briefly, TT (12 mg, batch no. FA 045644, gift from Sanofi-Pasteur) was converted to maleimide-activated TT. Synthetic SF2a S-acetylthioacetylated-penta-(28), deca-, and pentadecasaccharides (29), followed respectively by NH 2 OH and HCl (7.5 l of a 2 M solution in 1 M potassium phosphate buffer, pH 6) were added to the activated TT (0.5 M in 0.1 M potassium PBS, pH 6) in molar ratios ranging from 1:5 to 1:15, and the mixtures were stirred for 2 h at room temperature. Following dialysis against 3 ϫ 2 L of 0.05 M PBS, pH 7.4 at 4°C (MW cut-off 10,000 Da), and gel permeation chromatography on a Sepharose CL-6B column (1 m ϫ 160 mm) in 0.05 M PBS, pH 7.4, the conjugates were stored at 4°C in the presence of thimerosal (0.01%). SF2a OS/TT molar ratio was assessed by SELDI-TOF MS (Supplementary material 1). 5 
Biotinylated probes
Biotinylated penta-, deca-, and pentadecasaccharides were synthesized as described (27) . The biotinylated linker mimics (Supplementary material 2) 5 were prepared accordingly. Thus, Biot-Mal-linker was synthesized in two steps, providing Biot-Mal-NHOH as side-product. Hydrolysis of EZ-link PEO-maleimide activated biotin (Pierce) provided Biot-Mal-OH.
Immunogenicity studies
Seven-week old BALB/c mice were injected i.m. with AB(E)CD-TT, [AB(E)CD] 2 -TT, or [AB(E)CD] 3 -TT, three times at 3 wk intervals, followed by a fourth injection 1 mo after the third one, with the equivalent of 1, 2.5, or 10 g of carbohydrate hapten, as indicated, per mouse and per injection, in the absence of adjuvant. The anti-LPS and anti-OS induced Ab responses were assessed 1 wk after the third and fourth injections by ELISA as previously described (27) . Accordingly, to define the anti-linker Ab titers, biotinylated linker mimics (0.5 g/well) were coated on plates previously incubated with avidin (1 g/well, Sigma-Aldrich) for 1 h at 37°C. Anti-mouse IgG alkaline phosphatase-labeled conjugate (SigmaAldrich) was used as secondary Ab at a dilution of 1/5,000. For analysis of IgG subclasses, anti-mouse IgG1, IgG2a, IgG2b, and IgG3 alkaline phosphatase-labeled conjugates (Sigma-Aldrich) were used at a dilution of 1/5,000. For analysis of the cross-reactivity of mouse sera, plates were incubated with LPS purified from different Shigella strains as indicated. The Ab titer was defined as the last serum dilution given an OD of at least twice that of preimmune serum.
Analysis of O-SP recognition by glycoconjugate-induced sera
Purified LPS 2a (2 g/lane) was run in SDS-PAGE and silver-stained as previously described (30) . Following Western blotting, nitrocellulose membranes were incubated with sera from mice immunized with [AB(E)CD] 3 -TT or whole killed SF2a bacteria as control. Sera were tested using a similar anti-LPS 2a Ab titer. Anti-mouse Ig HRP-labeled conjugate (Amersham Biosciences) at a dilution of 1/5000 was used as secondary Ab.
Protective capacity of glycoconjugate-induced sera
To compare the protective capacity of anti-LPS 2a Abs induced upon immunization with AB(E)CD-TT, [AB(E)CD] 2 -TT, or [AB(E)CD] 3 -TT, mouse sera exhibiting a similar anti-LPS 2a Ab titer (1/12,800) were selected from each group of mice immunized with one of the conjugates. The selected immune sera (15 l) were mixed with 10 6 CFU of virulent SF2a bacteria (5 l) just before i.n. administration of the total 20 l to naive mice. Measurement of lung-bacterial load (CFU/lungs) was done at 24 h postinfection. Two control groups were included: one receiving bacteria previously incubated with sera from mice immunized with B(E)CD-TT, but negative for the anti-LPS 2a Ab response, and one receiving bacteria previously incubated with preimmune serum. Three independent experiments including seven mice per group were run for each immune serum tested. 3 by sera of naturally infected individuals ELISA was performed as described above using human sera from individuals naturally infected by SF2a against LPS 2a, biotinylated AB(E)CD, 3 OSs as coating Ags. Anti-human IgG alkaline phosphatase-labeled conjugate (Sigma-Aldrich) was used as secondary Ab at a dilution of 1/2500. Eight paired sera obtained from Israeli soldiers before starting training cycles under field conditions and 1 to 2.5 mo after suffering from culture-proven SF2a shigellosis were tested.
Recognition of AB(E)CD, [AB(E)CD] 2 , and [AB(E)CD]
[AB(E)CD] 2 , or [AB(E)CD]
Statistical analysis
Significant differences were established using the Student's t test. Values of p Ͻ 0.05 were considered to be significant.
Results
Recognition of AB(E)CD, [AB(E)CD] 2 , and [AB(E)CD] 3 by sera of naturally infected individuals
Characterization of SF2a-specific determinants was performed using protective murine mIgGs (27) . To assess whether the pentasaccharide AB(E)CD, the decasaccharide [AB(E)CD] 2 , and the pentadecasaccharide [AB(E)CD] 3 mimicking SF2a-specific determinants were the targets of the Ab response induced upon natural infection, ELISA was performed using a panel of human sera recovered from SF2a-naturally infected individuals and the corresponding preinfection sera as control. All infected patients elicited an anti-LPS 2a Ab response (Fig. 2) . Except for patient P8, all the postinfection sera tested had an increased anti-OS Ab response as compared with preinfection ones. For patients P1, P2, and P3, the anti-[AB(E)CD] 3 Ab response was higher than those directed against AB(E)CD and [AB(E)CD] 2 , those were similar except for P3 exhibiting a slightly higher anti-[AB(E)CD] 2 Ab titer (Fig. 2) . For patients P4 and P5, the anti-[AB(E)CD] 2 and anti-[AB(E)CD] 3 Ab responses were similar, and slightly higher than that measured for AB(E)CD. Finally, for patients P6 and P7, no difference was observed between the anti-OS Ab responses (Fig. 2) . These data show that AB(E)CD, [AB(E)CD] 2 , and [AB(E)CD] 3 , are targets of the Ab response elicited upon SF2a-natural infection. 5 The online version of this article contains supplemental materail. 3 -TT conjugates having an average carbohydrate to protein ratio of 14:1 based on colorimetric assay (31), were used to immunize mice four times at doses corresponding to 10 g of carbohydrate. To assess the protective efficacy of the anti-LPS 2a Abs induced upon immunization with those three conjugates, naive mice were passively i.n. administered with immune or preimmune sera previously incubated with virulent SF2a bacteria. Immune sera with the same anti-LPS 2a Ab titer, i.e., 1/12,800, were selected for each conjugate. It is noteworthy that the average of the anti-LPS 2a Ab titer induced by the three conjugates was previously shown to be 1/728, 1/5,200, and 1/26,000 for AB(E)CD-TT, [AB(E)CD] 2 -TT, and [AB(E)CD] 3 -TT, respectively (27) . For AB(E)CD-TT and [AB(E)CD] 2 -TT, only 7 and 20% of mice, respectively, raised an anti-LPS 2a Ab titer of 1/12,800. In contrast, in 93% of mice immunized with [AB(E)CD] 3 -TT, the anti-LPS 2a Ab titer was equal or superior to 1/12,800 (with 65%, superior to 1/12,800). Protection was evaluated by measuring the CFU/lungs at 24 h postinfection and a reduction factor was calculated as the ratio between CFU/lungs in naive mice passively administered with preimmune sera to that of naive mice passively administered with immune sera. Serum from mice immunized with B(E)CD-TT was used as a control because this conjugate does not induce any anti-LPS 2a Ab response (27) . A significant but low level of protection was observed for AB(E)CD-TT-induced Abs with only a 7-fold reduction in the bacterial load as compared with control group. The level of protection was significantly higher with [AB(E)CD] 2 -TTinduced Abs as compared with AB(E)CD-TT ( p ϭ 0.0023), but still only a 13-fold reduction in the bacterial load was measured. The best protection, i.e., a 45-fold reduction, was obtained with sera from mice immunized with [AB(E)CD] 3 -TT. The reduction factor was significantly higher than that measured with sera from mice immunized with AB(E)CD-TT ( p ϭ 1.8 ϫ 10 Ϫ6 ) and [AB-(E)CD] 2 -TT ( p ϭ 1.06 ϫ 10 Ϫ5 ), respectively (Fig. 3 ). Protection conferred with sera from mice immunized with [AB(E)CD] 3 -TT was shown to be dose-dependant because a 100 time-dilution of [AB(E)CD] 3 -TT-induced sera led to a 10-fold decrease of the reduction factor. These results demonstrate that, among the OSs tested, [AB(E)CD] 3 is the best functional mimic of the SF2a O-SP. Detailed analysis of parameters influencing the immunogenicity were then focused on [AB(E)CD] 3 -TT glycoconjugate.
Induction of a protective anti-SF2a Ab response by AB(E)CD-TT, [AB(E)CD] 2 -TT and [AB(E)CD] 3 -TT
Selected AB(E)CD-TT, [AB(E)CD] 2 -TT, or [AB(E)CD]
Recognition of SF2a O-SP chains by sera of mice immunized with [AB(E)CD] 3 -TT
LPS is associated to a ladder type profile derived from the heterogeneity in the number of RUs per O-SP chain when run in Tricine SDS-PAGE. For SF5a, for example, two major LPS populations coexist, with an average modal number of RUs of ϳ15 (mode A) and 100 (mode B) (30) . We investigated the length of LPS 2a chains recognized by [AB(E)CD] 3 -TT-induced Abs and wholekilled SF2a bacteria induced Abs. As observed in Fig. 4A , two major modal forms, A and B, were present for SF2a LPS. Upon immunoblotting, except for core recognition, modes A and B SF2a LPS were both recognized by sera from mice immunized with whole-killed SF2a bacteria (Fig. 4B, left panel) or [AB(E)CD] 3 -TT (Fig. 4B, right panel 
Anti-LPS 2a IgG subclasses induced by [AB(E)CD] 3 -TT
Analysis of the anti-LPS 2a IgG subclasses induced upon immunization of mice with [AB(E)CD] 3 -TT was performed by ELISA. For each mouse, the anti-LPS 2a IgG1 response was significantly predominant over that elicited for IgG2a, 2b, and FIGURE 2. Synthetic haptens corresponding to 1, 2, and 3 SF2a O-SP RU are recognized by sera of SF2a-naturally infected patients. Sera from SF2a-naturally infected patients were tested in ELISA using biotinylated AB(E)CD, [AB(E)CD] 2 , [AB(E)CD] 3 , and purified SF2a LPS as coating Ags. IgG Ab titer against each Ag was measured. Eight paired sera (P1-P8), obtained from Israeli soldiers before starting training cycles under field conditions and 1 to 2.5 mo after suffering from culture proven SF2a shigellosis, were tested. It is worth to mention that 2 mo after the boost, the anti-LPS 2a IgG response was only slightly lowered (data not shown).
Cross-reactivity of sera induced by [AB(E)CD] 3 -TT toward other prevalent S. flexneri LPS
To assess the serotype-specificity of the anti-LPS Abs induced by [AB(E)CD] 3 -TT, ELISA was performed using sera of [AB-(E)CD] 3 -TT-immunized mice and purified LPS from other S. flexneri serotypes as coating Ags. No Ab response against LPS 1b or LPS 3a, two other prevalent S. flexneri strains (12), was detected. The study was therefore extended to other S. flexneri serotypes. No cross-reactivity was detected using LPS purified from SF2b, 3b, 5b, and X strains, whereas SF5a and Y LPS were slightly recognized. Altogether, these results indicate that the Ab response elicited upon immunization of mice with [AB(E)CD] 3 -TT is highly specific for SF2a.
Influence of the dose on the immunogenicity of [AB(E)CD] 3 -TT
Preliminary immunogenicity data with [AB(E)CD] 3 -TT were obtained using 10 g of [AB(E)CD] 3 per mouse and per dose (27) . Following the same immunization protocol, immunogenicity of [AB(E)CD] 3 -TT was assessed using amounts of glycoconjugates corresponding to 1 and 2.5 g of [AB(E)CD] 3 per mouse and per dose. The anti-LPS 2a Ab titers, raised with these lower amounts of carbohydrate, were not significantly different from that induced with 10 g of hapten, both after the third dose and the boost ( 
Influence of carbohydrate hapten loading on the immunogenicity of [AB(E)CD] 3 -TT
As stated above, [AB(E)CD] 3 -TT conjugates used for previous studies (27) , and for those presented here, had an average ratio of 14:1 OS chains/protein. To assess the influence of [AB(E)CD] 3 loading on immunogenicity, new sets of [AB(E)CD] 3 -TT conjugates bearing an average hapten molar loading of two, eight, and 14 were synthesized and evaluated by immunizing mice with an equivalent of 10 g of OS per mouse and per dose. The [AB(E)CD] 3 -TT conjugate with a ratio of two induced no anti-OS Abs (data not shown), and consequently no anti-LPS 2a Abs (Fig. 7) . For a molar ratio of eight, a similar anti-LPS 2a Ab response was observed after the third immunization and the boost ( p ϭ 0.002), in contrast to ratio 14 for which a significant increase was observed after the boost ( p ϭ 0.008), giving rise to the best response observed so far. These results demonstrate that an average [AB(E)CD] 3 /TT ratio of 14 provided the best immunogen of all those tested. 3 -TT conjugates relies on the maleimide-thiol ligation chemistry, selected for its high chemoselectivity and high-yielding coupling efficacy at controlled pH. The N-(␥-maleimidobutyryloxy) amide linker used herein was selected based on the finding that use of the more flexible alkyl-type maleimide spacers could generally overcome the immunogenicity of cyclic maleimide linkers in animal models (32, 33) . However, linear maleimide linkers may also be immunogenic (6, 34) , checking whether it was the case with our [AB(E)CD] 3 -TT conjugate was therefore mandatory. To investigate the anti-linker Ab response, the corresponding Biot-Mal-linker derivative, bearing the whole 13 atom-long spacer present in [AB(E)CD] 3 -TT conjugates, was synthesized. Side-products derived from hydroxylamine addition onto maleimide (Biot-Mal-NHOH) or maleimide hydrolysis (BiotMal-OH) were also isolated because any side-product could be identified as a potential source of neo-epitopes (33) . Independently of the OS molar loading onto the protein, or of the amount of carbohydrate used per mouse per dose, no anti-linker IgG Ab was detected against any of the three newly synthesized biotinylated probes used as coating Ags (data not shown). These data indicate that upon immunization with [AB(E)CD] 3 -TT, there is no detectable Ab response induced against the N-(␥-maleimidobutyryloxy) amide linker or side-products thereof. Interestingly, the influence of the linker on immunogenicity may highly depend on the nature and intrinsic immunogenicity of the carbohydrate hapten. Along this line, we showed that neither [AB(E)CD] 2 -TT nor [AB(E)CD]-TT gave rise to detectable anti-linker Abs.
Analysis of the anti-linker Ab response induced by [AB(E)CD] 3 -TT
Construction of the [AB(E)CD]
Discussion
In the past decades, interest in synthetic microbial carbohydratebased vaccines, thus termed third generation polysaccharide vaccines, has emerged as one among the many exploding fields of carbohydrate medical applications. To our knowledge, only one such candidate vaccine has yet gone through clinical trials in the case of bacterial infections (8) . The resulting licensing of Quimi Hib in Cuba in 2003 demonstrates the potential of the strategy in humans. However, despite an increasing number of encouraging reports, efficient third generation bacterial polysaccharide vaccines remain at an early stage of development (7, 9, 10) . By demonstrating the induction of a protective anti-LPS Ab response against SF2a, using a conjugate incorporating a rationally designed synthetic OS mimic of LPS 2a, the current study provides an additional example of the potential of such an approach.
There is yet no established rule to define the appropriate hapten length resulting in optimal functional mimicry of the native Ag that would prevent from performing immunogenicity/protection studies. Thus, performing those studies, we showed that [AB(E)CD] 3 is the best mimic among the studied haptens. Indeed, [AB(E)CD] 3 -TT induced sera confer the best protection in mice, and we previously reported that [AB(E)CD] 3 -TT is the only conjugate among all those tested that induces an anti-LPS 2a immune response in 100% mice (27) . It is noteworthy that parameters such as antigenicity measured using mouse mIgGs specific for SF2a serotype and human sera, as well as structural data, would not have favored the selection of [AB(E)CD] 3 . Indeed, inhibition ELISA analysis showed either a similar recognition or a loss in recognition upon elongation of [AB(E)CD] 2 by one RU, depending on the mIgGs (Supplementary material  3) . 5 Besides, AB(E)CD, [AB(E)CD] 2 , and [AB(E)CD] 3 were similarly recognized by human sera from patients naturally infected with SF2a, demonstrating that O-Ag epitopes recognized by human sera are, to some extent, present in haptens corresponding to a small number of RUs. In addition, available structural data on [AB(E)CD] 2 and [AB(E)CD] 3 , in complex with one of the available protective mAbs, mIgG F22-4, demonstrated that the nine residue-epitopes that bind to mIgG F22-4 Fab are already present in the decasaccharide (35) . As an opening to challenge the topic, additional structural and physicochemical investigations are in progress to unravel the molecular basis for accurate mimicking of SF2a O-SP by [AB(E)CD] 3 .
Regarding the protective capacity of [AB(E)CD] 3 -TT induced sera, in contrast to reports showing that synthetic haptens corresponding to only one RU or less could provide Ab-mediated protection in animal models (36 -38) , at least two RUs were needed for SF2a, with three RUs giving rise to the best protection observed so far. Those data fit several observations indicating that a minimum of two contiguous RUs are required to induce antipolysaccharide Abs in the case of heteropolysaccharide Ags (39, 40) , although this is not always the case (38) . Besides, the increased protective capacity of [AB(E)CD] 3 -TT over [AB(E)CD] 2 -TT parallels data reported for H. influenzae b (41) , and the corresponding increased immunogenicity supports data described for S. dysenteriae 1 (40) . Alternative options toward additional increase of the protective anti-LPS 2a Ab response will be investigated (42) . Indeed, in direct support to our observations, protection against shigellosis is thought to be correlated to the level of anti-LPS Abs (17, 18) , although the threshold of the anti-LPS Ab response required to ensure protection is yet unknown. To further detail the protective anti-LPS Ab response induced by [AB(E)CD] 3 -TT, we observed that three immunizations were required to promote an optimal anti-LPS IgG response. An additional boost only slightly increased the anti-LPS IgG titer by a factor of two to three. In full agreement with a T-dependent immune response, an anti-LPS IgM titer was detected after the first immunization only (data not shown).
Numerous factors, including the polysaccharide itself, influence the pattern of IgG subclass response (18) . Analysis of the anti-LPS IgG subclasses revealed that [AB(E)CD] 3 -TT induces in mice a Th2-type immune response mainly mediated by IgG1. Interestingly, this particular profile mimics the Th2-type response observed in humans following natural SF2a infection (18) or immunization with a detoxified SF2a LPS-protein conjugate (43) . Although serotyping analysis has demonstrated that S. flexneri OSPs share several epitopes (15) , data on the field suggest that protection induced by natural infection is serotype-specific. Immunization in experimental models with vaccine candidates was only occasionally shown to induce cross-protection (44, 45) . Herein, we show that [AB(E)CD] 3 -TT induced sera do not significantly crossreact with serotypes 1b, 2a, 3a, 5a, 5b, X, and Y LPSs. Overall, these data suggest that [AB(E)CD] 3 -TT induces in mice an Ab response that is highly SF2a-oriented, as observed in naturally infected patients.
Shortening the hapten length also impacts on the number of exposed carbohydrate epitopes, and consequently on the carrier and linker relative visibility by the host's immune system, possibly leading to divergence of the Ab response. For example, in the case of a hapten possessing a low inherent immunogenicity, induction of anti-linker Abs was reported to be detrimental to induction of anti-hapten Abs (33, 34) . Along this line, it is noteworthy that no Ab response was induced against the maleimide linker used for conjugation of [AB(E)CD] 3 to TT. As additional support to this finding, the same observation remained true if shorter haptens, one and two RUs, respectively, were involved (data not shown). Interestingly, glycoconjugates prepared using maleimide linkers were occasionally administered in humans with no reported negative influence on hapten-immunogenicity (8, 46) . Furthermore, the routine administration of Quimi Hib to infants (8) suggests that a maleimide linker is indeed appropriate for use in humans.
In the present stage of development of synthetic carbohydrateprotein conjugate vaccines, additional investigation is required to better understand the impact of interdependent parameters on immunogenicity and protective efficacy. Having selected TT, a medically acceptable carrier for use in human, efforts were put on analyzing the amount per dose and molar loading. There is no established correlation between hapten loading and protective efficacy (37, 47, 48) . Here, we clearly show that it is a critical parameter. The [AB(E)CD] 3 -TT conjugate with a hapten loading of two was the less potent one, failing to induce an anti-LPS or anti-[AB(E)CD] 3 IgG response when administered three times at 10 g carbohydrate/dose. Interestingly, after the third immunization there was no significant difference between the immunogenicity of the [AB-(E)CD] 3 -TT conjugates displaying a hapten molar loading of 8 and 14, respectively, suggesting that this range of hapten molar loading induces appropriate B cell receptor cross-linking, without masking important Th epitopes. However, despite an increased immunogenicity observed after the boost for the [AB(E)CD] 3 -TT conjugate having a 14:1 OS chains/protein ratio, molar loading resulting in maximal immunogenicity remains yet unknown. Additional improvement may therefore be in reach, as illustrated in an elegant study on S. dysenteriae type 1 where the hapten loading was increased to a point resulting in a decrease in immunogenicity (40) . Identifying the highest reproducible hapten molar loading inducing the highest anti-LPS Ab response is important to the issue of carrier overloading (49) . Indeed, using glycoconjugates of similar potency but increased hapten loading would result in lowering the amount of carrier for a given administered amount of carbohydrate.
Regarding the influence of the dose, for the most recently licensed polysaccharide conjugate vaccines, for example Prevnar, the amount of polysaccharide per dose varies from 2 to 4 g in average, depending on the polysaccharide chemical structure. Analogously, lowering the amount of immunogen administered to animal models is the general tendency. Along this line, our data showing that when used at doses corresponding to 2.5 or 1 g of synthetic carbohydrate, [AB(E)CD] 3 -TT induces high anti-LPS IgG titers in mice are consistent with most recent investigations on synthetic OS-based conjugate vaccines (37, 40) . To our knowledge, reports on immunization with 1 g carbohydrate amounts or less are scarce but support our findings (37, 41) . For example, a synthetic tetrasaccharide-CRM 197 type 3 pneumococcal conjugate was shown to induce antipolysaccharide Ab titers which were high enough to confer protective immunity against intraperitoneal challenge with a lethal dose of S. pneumoniae type 3 when used in mice at doses corresponding to 0.25 g of carbohydrate (37) . It is noteworthy that data suggest that synthetic OS-based conjugate vaccines are equally or even more strongly immunogenic in comparison to their native polysaccharide conjugate counterpart (8, 40) .
The poor accessibility of well-defined complex oligosaccharides has for long impaired investigations on the potential of synthetic OS-based conjugate vaccines for medical applications. This is no longer the case, as demonstrated by the number of reports (10) and the recent breakthrough in the field of Haemophilus influenzae b glycoconjugate vaccines (8) . Along this line, the pentadecasaccharide [AB(E)CD] 3 was initially synthesized in 44 chemical steps following a convergent approach based on three building blocks (29) . The synthesis was thought compatible with scale-up. Nevertheless, additional validation of the whole strategy was, in our opinion, a prerequirement. In the course of this study, we could fully reproduce and even improve the reported synthesis. The pentadecasaccharide is now obtained in 40 steps, which include several improvements (T. H. Kim and L. A. Mulard, unpublished results).
In conclusion, considering the drawbacks of orally administered, live attenuated Shigella vaccine candidates (14) , and the absence of published data on the efficacy of Shigella-detoxified LPS-conjugate vaccines in young children living in endemic areas, the current study emphasizes the potential of selected synthetic oligosaccharides as immunogenic mimics of the bacterial surface polysaccharide. The proof of concept in humans is needed urgently to definitely establish the development of such rationally designed synthetic carbohydrate-based conjugates as a promising alternative strategy for Shigella vaccines.
